Sun, Sep 21, 2014, 7:05 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. (FOLD) Message Board

jrdelane 676 posts  |  Last Activity: 16 hours ago Member since: Dec 5, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Looks like they've got AE-37 to compete with Neuvax. Copied this from their site: AE37 is not the only peptide vaccine in development in the adjuvant setting. Galena BioPharma's NeuVax (E75) is currently in phase III trials for the treatment of various cancers. NeuVax is also derived from the HER2 protein but is MHC Class I restricted. Thus far, there is evidence of prevention of disease recurrence with NeuVax as well. Another vaccine, GP2 (which like E75 is a HER2-derived vaccine), is being developed by Antigen Express. - See more at: http://www.cancernetwork.com/breast-cancer/asco-ae37-peptide-vaccine-may-help-prevent-breast-cancer-recurrence#sthash.EtEq7Kaw.dupe

    Sentiment: Strong Buy

  • Reply to

    congrats to Donaldtay1 on his good news

    by brightsmile213 Aug 25, 2014 4:29 PM
    jrdelane jrdelane Aug 25, 2014 11:48 PM Flag

    Our money pays psychic dividends now, real $returns will come later, delayed gratification is a Godly thing bashers can't grasp!

    Sentiment: Strong Buy

  • jrdelane by jrdelane Jun 27, 2014 2:30 PM Flag

    OK, so MM did the quick morning run to pick up shares via stop losses, now it's time to resume the run up. Good luck longs, time is on our side, we aren't paying to borrow shares, and the trend is our friend.

    Sentiment: Strong Buy

  • No other MS drug currently on the market has demonstrated
    significant neuroprotection and the potential positive impact on cognition. Dr. Voskuhl and her potential partners
    are very intrigued. In fact, Dr. Voskuhl emailed me yesterday, stating only further emphasis is the fact that this
    data leads the field into new paths of treatment for MS that are not merely anti-inflammatory but also
    neuroprotective. Such neuroprotective effects of Trimesta may ultimately be relevant to Alzheimer’s disease and
    other neurodegenerative diseases characterized by cognitive decline – unquote. We look forward to evaluating
    this exciting clinical result as well as exploring potential unique regulatory strategies going forward.
    In summary, the multiple positive efficacy signals from this placebo-controlled study are strong. Neurologists
    and MS specialists saw exactly what they hoped to see from this study and more in the area of cognitive
    improvement. Dr. Voskuhl, Synthetic Biologics, as well as several potential partners believe we are on the right
    track in developing Trimesta as an adjunctive MS therapy for women. We look forward to updating shareholders
    on our discussions with potential MS partners as well as our plans to advance Trimesta in the clinic based on
    these clinically significant Phase II results.

    Sentiment: Strong Buy

  • One post about this, don't give him the attention, that is what he wants, ignore him, don't red thumb or read his posts. Let him wither from zero attention, and quit wasting board space posting about him, please! Talk about your investment, or the company, or the market, but not personalities. Small minds do that, is that how you want to appear, same as him?

    Sentiment: Strong Buy

  • Reply to

    Since April

    by dolfan2323 Jul 16, 2014 1:39 PM
    jrdelane jrdelane Jul 16, 2014 4:44 PM Flag

    You don't consider the shelf registration to be "bad news"? Granted, they haven't diluted yet, but registering the intent to dilute to that magnitude is not greeted with enthusiasm by investors. I think it qualifies as bad news.

    Sentiment: Hold

  • Unless you were expecting the quick retrace up like the last rally to .97, hopefully you signed on for a long term investment. This is going to take some time to develop, you can see we are reaching the designated targets as Nasrat said. I did hear him say he is open to whatever is best for creating shareholder vlue, and if that means partnership or buyout, he would just retire early if taken out. I like his transparency, and further he stated he is with ELTP as long as they need him (to advance the pipeline to complete what they've started). He's all about creating shareholder value, because he is paid in shares and not cash. I think the man has a lot of integrity, and is laying down the foundations of a very successful company. I thought he handled callers questions well, and that his analogy of the mansion without a roof was excellent. When he arrived, ELITE had to have the roof added. Now the Company has straightened out their balance sheet and they have the cash to do what they need to do. Give the man credit, and time to execute the business plan.

    Sentiment: Hold

  • Elite's ART technology can be applied to many drugs and de-risk opioids. The time is right, the FDA and politicians want safer medications, anti-abuse deterrent ART technology will not be denied!

    March 27, 2014: Governor Patrick Bans Zohydro

    Governor Deval Patrick issued a Declaration of Emergency regarding opioid addiction and concluded that "an emergency exists which is detrimental to the public health" in Massachusetts. In conjunction with this declaration and on the same day, Massachusetts Department of Public Health Commissioner Cheryl Bartlett approved an emergency order banning Zohydro ER's from being prescribed, dispensed, and administered.

    Governor Patrick's reasoning for declaring emergency on opioid addiction in his state centered on three citations: 1) 668 Massachusetts residents died from unintentional opioid overdoses in 2012, 2) opioid abuse has increased due to the proliferation of prescriptions of opioid pain relievers, and 3) opioid use serves as gateway to heroin use.

    Sentiment: Strong Buy

  • jrdelane by jrdelane Jun 24, 2014 12:20 PM Flag

    What I see is our stock is in demand and is getting bought heavily on the dips. I saw it here and agree that the new floor is now $0.42. Today's lower open gives some new shareholders a nice entry and also gives a healthy breather to the share price, up over 20% in two weeks. I'd rather see a more gradual gain in our share price than go parabolic and not be able to hold it. This is going to be a huge year for Elite, anyone reading this, if you're long you are due congratulations for seeing this. If you are short, I offer my condolences because you are going to get buried if you don't cover and soon!

    Sentiment: Strong Buy

  • Reply to

    I am sick of rfwelsch mindless pumping...

    by diwannewyork Aug 11, 2014 8:37 AM
    jrdelane jrdelane Aug 11, 2014 3:30 PM Flag

    Yes, it's what makes a market, buyers and sellers. That poster has never added any value to this board. Thanks for all your informative posts. We've been tested, now is time to get rewarded, now meaning going forward way beyond this next conference call and into the next year or three.

  • This company is entering a good phase ahead, cited already here. My position just entered the green Zone first time since I started buying first lot at .70, then more as she bottomed. Good luck longs!

  • Reply to

    Bought More

    by kdalglish14 Aug 27, 2014 4:14 PM
    jrdelane jrdelane Aug 27, 2014 4:39 PM Flag

    I agree, left and came back to see we only lost a couple cents, after being down .07 I think of it as a win. The challenge between catalysts is always holding onto the gains, and with IDRA, the catalysts are so far apart, that's why the shorts have had their way with it. There's a lot of well informed investors here, in retail, glad they have done their DD and are willing to share their views here.

    Sentiment: Strong Buy

  • Reply to

    16 days still no data

    by gavin020207 Jul 17, 2014 12:41 AM
    jrdelane jrdelane Jul 21, 2014 11:02 AM Flag

    I was at the Angels baseball game yesterday against the Mariners, and it ended on the last pitch when the Angel's scored the winning run in the bottom of the 9th inning. To use an analogy, here we are in the early innings of the game, and you are wanting to score winning runs now! Let the game play out, this one has got the right elements for success, admit it or you wouldn't be here. Just can't force it, anyone ever tell you it takes patience to invest in biotech stocks?

  • Reply to

    With GALE the skies the limit. Must read.

    by mrtipars Jul 6, 2014 7:59 PM
    jrdelane jrdelane Jul 7, 2014 11:58 PM Flag

    I am confident in GALE being a great investment for my family. This enthusiastic post is reflective of many solid opinions that may very well prove out. Thanks for your summary!

    Sentiment: Strong Buy

  • Reply to

    Glad to still be here. For the Longs

    by epjheatingandair Jun 23, 2014 11:09 PM
    jrdelane jrdelane Jun 24, 2014 2:16 AM Flag

    I can relate! It's been a very wild ride, and besides getting our share price back up, what would really make my day would be to hear of AF being charged, convicted, and forever banned from writing his sell side Biotech Mailbag column ever again.

    Sentiment: Buy

  • Reply to

    MAY I PRESENT THE LIST!!! LONG AND STRONG!!!

    by visceraljunket Jul 22, 2014 11:47 PM
    jrdelane jrdelane Jul 23, 2014 2:05 AM Flag

    Thanks VJ, see all winners on other side of results! To the top!

    Sentiment: Strong Buy

  • Reply to

    Werbowksky v. Hillsberg et al

    by fugitive6129 Aug 6, 2014 6:30 PM
    jrdelane jrdelane Aug 6, 2014 6:33 PM Flag

    Won't pay to file stupid baseless lawsuits. How many others are due to follow?

    Sentiment: Strong Buy

  • Doji candle, closed slightly lower than it opened, at same price as yesterday's close, creating a black body doji candle, often represents a change in trend. Look for higher open and close next week. This week was tainted with broad market weakness, driving our stock down 7 cents on the week. Not surprising, only news was CEO hire Amick, and now we wait to see when the news comes. Buyout or partnership likely IMHO. My guess is it's JNJ, but AGN is also likely. GLTA.

    Sentiment: Strong Buy

  • With Zytiga's well known side effects, soft sales trend, and limited efficacy, why wouldn't this be an obvious acquisition for JNJ? Granted they don't want to destroy their sales but maybe they market both, in an effort to have a better grasp on the prostate cancer market, plus they can use the big tax write off, and make good use of the patent portfolio? So, JJ and BOD are putting the placeholder Amick into position as they finalize the deal, all to be announced by August 15th, after which they do their quarterly report.

    Sentiment: Strong Buy

  • What happened after hours is PBYI, and maybe investors seeing that and understanding GALE is way undervalued after a much tempered regular session, a lot of folks got excited and went shopping for GALE shares?

    Sentiment: Strong Buy

FOLD
6.61-0.09(-1.34%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.